Expertise in
2
conditions

Dr. Michael L. Maitland

Oncology
8081 Innovation Park Dr, 
Fairfax, VA 
Accepting New Patients
Offers Telehealth
Expertise in
2
conditions
8081 Innovation Park Dr, 
Fairfax, VA 

Overview

Michael Maitland is an Oncologist practicing medicine in Fairfax, Virginia.

Dr. Maitland is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer.

He is actively involved in clinical research, co-authoring 63 peer reviewed articles and participating in 8 clinical trials. Dr. Maitland is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in IL

Fellowships

University of Chicago Medical Center Training Specialty: Medical Oncology 7/01/2003 - 6/30/2005
Memorial Sloan Kettering Cancer Center Training Specialty: Medical Oncology 6/1/2002 - 7/31/2003

Hospital Affiliations

Inova Fairfax Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
View 1 Less Insurance Carrier -

Locations

Inova Schar Cancer Institute
8081 Innovation Park Dr, Fairfax, VA 22031

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Vorinostat and Carboplatin or Vorinostat and Paclitaxel in Patients With Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study
Vorinostat and Carboplatin or Vorinostat and Paclitaxel in Patients With Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug, Other
Study Phase: Phase 1
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

63 Total Publications

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 03, 2025
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

MedStar Georgetown University Hospital

3800 Reservoir Rd NW, 
Washington, DC 
 (8.8 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Cheson is an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Cheson is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Non-Hodgkin Lymphoma. Dr. Cheson is currently accepting new patients.

Expertise in
19
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Expertise in
19
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Referral may be required

Office

8906 Bradmoor Dr, 
Bethesda, MD 
 (11.2 miles away)
301-496-7387
Languages Spoken:
English

Brigitte Widemann is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Widemann is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Medullary Thyroid Carcinoma, and Thyroidectomy.

Expertise in
87
conditions
Expertise in
87
conditions
Referral may be required

Virginia Cancer Specialists

8613 Route 29, 200, 
Fairfax, VA 
 (1.8 miles away)
571-350-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexander Spira is an Oncologist practicing medicine in Fairfax, Virginia. Dr. Spira is highly rated in 87 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Spira is currently accepting new patients.

Frequently Asked Questions about Dr. Michael L. Maitland

How do I make an appointment with Dr. Michael L. Maitland?

You can book an appointment with Dr. Michael L. Maitland by calling their office at 571-472-1180. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael L. Maitland a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael L. Maitland is classified as an Advanced expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael L. Maitland specialize in?

While Dr. Michael L. Maitland is a Oncology, they have specific expertise in Endometrial Cancer, Ovarian Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Michael L. Maitland participate in research or clinical trials?

Yes. Dr. Michael L. Maitland has published 63 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Michael L. Maitland's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael L. Maitland accept my insurance?

Dr. Michael L. Maitland accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 571-472-1180 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Maitland's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile